Clinical study to measure the impact of using AI in patients with lung nodule.
Not Applicable
- Registration Number
- CTRI/2023/04/051702
- Lead Sponsor
- AstraZenca
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Patients diagnosed with incidental pulmonary nodules on CXR by qXR and confirmed by the radiologist at the site with nodule size =8 and =30 mm.
Exclusion Criteria
1. Any medical or other contraindications for a CT scan
2. Nondigital CXR
3. CT scan is done more than 6 months after CXR
4. Patients with already diagnosed LC
5. The patients referred for an X-Ray for a suspicious LC
6. A patient who already participated in the study.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1. PPV of qXR-LNMS using a panel of radiologists assigning high-risk based on CT (done <br/ ><br>within 180 days from Xray) as the reference standard <br/ ><br>2. NPV of qXR-LNMS using panel of radiologists assigning low-risk based on CT (done <br/ ><br>within 180days from Xray) as reference standardTimepoint: One year
- Secondary Outcome Measures
Name Time Method 1. PPV of qXR-LNMS using panel of radiologists assigning Lung-RADS4A based on CT as reference standard <br/ ><br>2. PPV of qXR-LNMS using panel of radiologists assigning Lung-RADS4A based on CT as reference standard <br/ ><br>3. To assess the correlation of qXR-LNMS and the Mayo clinic model <br/ ><br>4. Clinically (2yr Follow Up) proven basedTimepoint: 1,2,3 - In one year. <br/ ><br> <br/ ><br>4 - Three years.